News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
305,990 Results
Type
Article (18368)
Company Profile (118)
Press Release (287495)
Multimedia
Podcasts (73)
Webinars (14)
Section
Business (95518)
Career Advice (1076)
Deals (16938)
Drug Delivery (83)
Drug Development (41384)
Employer Resources (80)
FDA (7123)
Job Trends (7096)
News (167558)
Policy (18825)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (848)
Accelerated approval (15)
Adcomms (9)
Allergies (75)
Alliances (24839)
ALS (76)
Alzheimer's disease (710)
Antibody-drug conjugate (ADC) (110)
Approvals (7296)
Artificial intelligence (212)
Autoimmune disease (49)
Automation (12)
Bankruptcy (282)
Best Places to Work (5092)
BIOSECURE Act (9)
Biosimilars (133)
Biotechnology (49)
Bladder cancer (55)
Brain cancer (34)
Breast cancer (185)
Cancer (1539)
Cardiovascular disease (163)
Career advice (926)
Career pathing (20)
CAR-T (61)
CDC (13)
Cell therapy (197)
Cervical cancer (10)
Clinical research (35799)
Collaboration (764)
Compensation (361)
Complete response letters (36)
COVID-19 (1097)
CRISPR (47)
C-suite (459)
Cystic fibrosis (65)
Data (2173)
Denatured (19)
Depression (64)
Diabetes (153)
Diagnostics (1677)
Digital health (11)
Diversity (2)
Diversity, equity & inclusion (23)
Drug discovery (122)
Drug pricing (130)
Drug shortages (20)
Duchenne muscular dystrophy (103)
Earnings (36548)
Editorial (37)
Employer branding (5)
Employer resources (74)
Events (43188)
Executive appointments (548)
FDA (8387)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (7)
Funding (489)
Gene editing (79)
Generative AI (22)
Gene therapy (244)
GLP-1 (513)
Government (1873)
Grass and pollen (6)
Guidances (191)
Healthcare (5030)
HIV (13)
Huntington's disease (16)
IgA nephropathy (42)
Immunology and inflammation (82)
Immuno-oncology (17)
Indications (58)
Infectious disease (1175)
Inflammatory bowel disease (82)
Inflation Reduction Act (8)
Influenza (28)
Intellectual property (118)
Interviews (177)
IPO (6595)
IRA (40)
Job creations (2215)
Job search strategy (806)
JPM (37)
Kidney cancer (9)
Labor market (29)
Layoffs (275)
Leadership (17)
Legal (6747)
Liver cancer (25)
Longevity (9)
Lung cancer (219)
Lymphoma (145)
Machine learning (13)
Management (27)
Manufacturing (435)
MASH (76)
Medical device (2044)
Medtech (2052)
Mergers & acquisitions (10700)
Metabolic disorders (516)
Multiple sclerosis (59)
NASH (14)
Neurodegenerative disease (118)
Neuropsychiatric disorders (45)
Neuroscience (1238)
Neurotech (1)
NextGen: Class of 2026 (2104)
Non-profit (1071)
Now hiring (17)
Obesity (273)
Opinion (203)
Ovarian cancer (68)
Pain (111)
Pancreatic cancer (60)
Parkinson's disease (109)
Partnered (16)
Patents (245)
Patient recruitment (145)
Peanut (17)
People (31899)
Pharmaceutical (65)
Pharmacy benefit managers (22)
Phase 1 (9363)
Phase 2 (15284)
Phase 3 (13672)
Pipeline (2170)
Policy (174)
Postmarket research (1527)
Preclinical (3743)
Press Release (27)
Prostate cancer (92)
Psychedelics (19)
Radiopharmaceuticals (151)
Rare diseases (419)
Real estate (2865)
Recruiting (31)
Regulatory (12222)
Reports (15)
Research institute (774)
Resumes & cover letters (145)
Rett syndrome (15)
RNA editing (6)
RSV (25)
Schizophrenia (80)
Series A (84)
Series B (53)
Service/supplier (3)
Sickle cell disease (50)
Special edition (12)
Spinal muscular atrophy (94)
Sponsored (18)
Startups (1775)
State (2)
Stomach cancer (5)
Supply chain (54)
Tariffs (72)
The Weekly (52)
Vaccines (348)
Venture capital (39)
Weight loss (175)
Women's health (31)
Worklife (6)
Date
Last 7 days (210)
Last 30 days (812)
Last 365 days (11822)
2026 (1094)
2025 (12127)
2024 (14180)
2023 (16393)
2022 (22252)
2021 (22733)
2020 (21770)
2019 (17879)
2018 (13879)
2017 (15345)
2016 (14572)
2015 (17000)
2014 (13605)
2013 (11609)
2012 (12406)
2011 (12941)
2010 (11754)
Location
Africa (448)
Alabama (22)
Alaska (4)
Arizona (84)
Arkansas (4)
Asia (22071)
Australia (3061)
California (3642)
Canada (1597)
China (578)
Colorado (165)
Connecticut (147)
Delaware (134)
Europe (45211)
Florida (662)
Georgia (86)
Hawaii (2)
Idaho (13)
Illinois (388)
India (44)
Indiana (262)
Iowa (2)
Japan (250)
Kansas (80)
Kentucky (20)
Louisiana (5)
Maine (3)
Maryland (467)
Massachusetts (2910)
Michigan (56)
Minnesota (185)
Mississippi (1)
Missouri (36)
Montana (10)
Nebraska (8)
Nevada (19)
New Hampshire (9)
New Jersey (1541)
New Mexico (8)
New York (1093)
North Carolina (657)
North Dakota (2)
Northern California (1662)
Ohio (100)
Oklahoma (5)
Oregon (19)
Pennsylvania (916)
Puerto Rico (13)
Rhode Island (18)
South America (642)
South Carolina (13)
Southern California (1581)
Tennessee (56)
Texas (535)
United States (14498)
Utah (77)
Virginia (166)
Washington D.C. (48)
Washington State (288)
West Virginia (1)
Wisconsin (41)
Wyoming (1)
305,990 Results for "cour pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
COUR Pharma Publishes Peer-Reviewed Data in Science Advances
January 29, 2026
·
3 min read
Podcast
A Conversation With Dannielle Appelhans, CEO of COUR
In the first podcast in a special series focused on
BioSpace
’s NextGen Class of 2025, Senior Editor Annalee Armstrong speaks with Dannielle Appelhans, CEO of COUR.
February 18, 2025
·
1 min read
·
Annalee Armstrong
NextGen
After 10 Years of Hard Work, COUR Treads Into Pharma’s Myasthenia Gravis Territory
COUR Pharmaceuticals has been around a while, but not until last year did the company solidify behind its ultimate mission with a series A raise.
February 18, 2025
·
2 min read
·
Annalee Armstrong
Press Releases
COUR Pharma Secures FDA Orphan Drug Designation for CNP-106 in Generalized Myasthenia Gravis
October 2, 2025
·
3 min read
Business
COUR Pharmaceuticals Appoints Tim Walbert to its Board of Directors
COUR Pharmaceuticals announced the appointment of Tim Walbert, an industry veteran with more than 30 years of leadership experience in biotech, to its Board of Directors, effective immediately.
June 26, 2024
·
3 min read
Immunology & inflammation
Roche Partners With COUR in Autoimmune Deal Potentially Worth More Than $900M
The collaboration will see COUR and Roche’s Genentech leverage the biotech’s antigen-specific immune tolerance platform to develop and commercialize therapies for an undisclosed autoimmune disease.
December 3, 2024
·
1 min read
·
Heather McKenzie
Press Releases
COUR Pharma Doses First Patient in Clinical Trial Evaluating CNP-103 in People Recently Diagnosed with Type 1 Diabetes
August 20, 2025
·
3 min read
Business
COUR Pharmaceuticals Appoints Paul M. Peloso, MD, as Chief Medical Officer
COUR Pharmaceuticals announced the appointment of Paul M. Peloso, MD, a seasoned drug developer with more than 20 years of experience advancing multiple therapeutic candidates through market approval, as chief medical officer.
May 21, 2024
·
4 min read
Press Releases
COUR Pharmaceuticals Secures FDA Clearance of IND Application for CNP-103 in Type 1 Diabetes
February 4, 2025
·
3 min read
BioMidwest
COUR Pharmaceuticals Secures $105 Million in Series A Financing Co-Led by Lumira Ventures and Alpha Wave Ventures
COUR Pharmaceuticals announced the closing of a Series A investment round, securing approximately $105 million in financing.
January 30, 2024
·
3 min read
1 of 30,599
Next
